# Instil Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/instil-bio

- Industry: Biotechnology
- Headquarters: Dallas, US
- Website: www.instilbio.com
- Total disclosed funding: $356M
- Latest round: Series C (Dec 29, 2020)
- Investors on record: 1

## About

Instil Bio, Inc. is a US-based clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment, with a focus on bispecific antibodies that enhance immune responses against tumors.Founded in 2018 in Dallas, US, Instil Bio, Inc. is a clinical-stage biopharmaceutical company specializing in cancer therapies. The company raised USD 320 mn in its IPO on March 22, 2021, selling 16 million shares at USD 20 each. The firm has completed 5 deals to date.Instil Bio is a clinical-stage biopharmaceutical company specializing in innovative therapies, particularly its lead asset, AXN-2510. This bispecific antibody targets both PD-L1 and VEGF, addressing critical needs in solid tumor cancer treatment. AXN-2510 is currently undergoing various clinical trials for multiple solid tumor types, primarily serving healthcare providers and oncology specialists in North America and select Asian markets.In 2020, Instil Bio generated revenue of USD 138,000, with an EBITDA of USD -73,541,000. The company primarily generates revenue through strategic partnerships, licensing agreements, and collaborations with larger pharmaceutical firms, facilitating the development and commercialization of AXN-2510.Instil Bio plans to leverage the recent IPO funding of USD 320 mn to accelerate the clinical development of AXN-2510 and expand its market presence. The company is targeting new geographic markets in Asia for its therapies and aims to advance product development and launch timelines. The funding will support ongoing clinical trials and enhance operational capabilities, positioning Instil Bio for further growth in the oncology market.

## Funding rounds

- Series C, Dec 29, 2020, $185M — HBM Partners
- Series B, Jun 29, 2020, $170M — HBM Partners

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series C